Chemo-Immunotherapy for Non-Driver Metastatic Lung Cancer

Chemo-Immunotherapy for Non-Driver Metastatic Lung Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Nondriver Metastatic NSCLC: Evolving Treatment Paradigm

July 10th 2018

EP. 2: KEYNOTE-189: Chemotherapy and Pembrolizumab in mNSCLC

July 10th 2018

EP. 3: Optimizing Use of the KEYNOTE-189 Regimen in mNSCLC

July 10th 2018

EP. 4: Chemotherapy + Pembrolizumab: A New Standard of Care?

July 10th 2018

EP. 5: Frontline Therapeutic Decisions for Nondriver mNSCLC

July 10th 2018

EP. 6: Quality of Life's Role in Treating Nondriver mNSCLC

July 10th 2018

EP. 7: CheckMate-227: Nivolumab + Ipilimumab in mNSCLC

July 10th 2018

EP. 8: IMpower150: Quadruplet Therapy for Nonsquamous mNSCLC

July 10th 2018

EP. 9: Managing the IMpower 150 Regimen in Nonsquamous mNSCLC

July 10th 2018

EP. 10: Molecular Testing's Role in Non-Small Cell Lung Cancer

July 10th 2018

EP. 11: Non-Small Cell Lung Cancer: Other Actionable Mutations

July 10th 2018

EP. 12: Nondriver mNSCLC: Incorporating Trial Data into Practice

July 10th 2018

EP. 13: Sequencing Through Multiple Relapses in Nondriver mNSCLC

July 10th 2018

EP. 14: Advancing the Treatment of Nondriver Metastatic NSCLC

July 10th 2018

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma